Target intelligence / Profile preview

Dengue virus serotype 2 envelope protein (DENV-2 E)

Target
DENV-2 E
Molecular classification
Viral protein, Viral envelope protein, Glycoprotein, Other
01

Overview

The Dengue virus serotype 2 envelope protein (DENV-2 E) is the major structural glycoprotein found on the outer surface of the DENV-2 virion. It plays a critical role in the viral life cycle by mediating host cell receptor binding, attachment, and subsequent low-pH-triggered membrane fusion within the endosome to release the viral genome into the host cytoplasm. Structurally, the E protein exists as a flat homodimer on mature virions and undergoes a major conformational transition to a post-fusion homotrimer during entry. Because of its essential role in viral entry and its high exposure on the virion surface, DENV-2 E is a primary target for neutralizing antibodies, therapeutic monoclonal antibodies (such as VIS513 and HMAb 2D22), and small-molecule fusion inhibitors. It is also the key antigen component in licensed vaccines like Dengvaxia and Qdenga, which aim to elicit protective neutralizing antibody responses. However, targeting this protein carries significant therapeutic challenges, most notably antibody-dependent enhancement (ADE), where sub-neutralizing or cross-reactive antibodies facilitate viral entry into Fc-receptor-bearing cells, potentially leading to severe dengue hemorrhagic fever or dengue shock syndrome.

Other names
Dengue virus type 2 envelope proteinDENV-2 envelope proteinDENV-2 E proteinDengue virus serotype 2 envelope glycoprotein EEnvelope protein EDENV2-ENV
02

Mechanism of action

Drugs and vaccines targeting the Dengue virus serotype 2 envelope protein work by either blocking viral entry (by preventing host cell receptor binding, attachment, or low-pH-mediated membrane fusion) or by acting as immunogens in vaccines to elicit protective neutralizing antibody responses.

03

Biological functions

Viral attachmentMembrane fusionViral entryHost-virus interactionImmune responseOther
04

Disease associations

InfectionDengue feverDengue hemorrhagic feverDengue shock syndrome
05

Safety considerations

Antibody-dependent enhancement (ADE) of infectionIncreased risk of severe dengue in seronegative individualsViral resistance mutations (escape mutants)Serotype-specific vs. cross-reactive immune responses
06

Interacting drugs

Dengvaxia (CYD-TDV)

6 more in the full profile.

07

Biomarkers

DENV-2 viral loadDENV-2 RNAAnti-DENV-2 neutralizing antibodiesDENV-2 envelope protein antigen

Beyond the preview

Go deeper on Dengue virus serotype 2 envelope protein (DENV-2 E).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dengue virus serotype 2 envelope protein (DENV-2 E).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call